Last reviewed · How we verify

NCT05009186

Changing of Prostate Specific Antigen Value in Patients With Covid-19

Status unknown NA Last updated 17 August 2021
What this trial tests

NA trial testing PSA value in Covid19 in 100 participants. Status unknown.

Timeline
1 April 2020
Primary endpoint
1 October 2021
1 October 2021

Quick facts

Lead sponsorSaglik Bilimleri Universitesi
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment100
Start date1 April 2020
Primary completion1 October 2021
Estimated completion1 October 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Saglik Bilimleri Universitesi — full company profile →

Who can join

Adults 45 to 70, male only, with Covid19 or Prostate Specific Antigen. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19. In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Saglik Bilimleri Universitesi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05009186.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing